Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast - HER2 Support Group Forums

		HER2 Support Group Forums > General Cancer News
Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast

General Cancer News Latest Breast Cancer News from Moreover Technologies

Reply

07-25-2014, 02:21 AM	#1
News Senior Member Join Date: Oct 2007 Posts: 18,941	Phase 3 trial: NEXAVAR tablets fail to meet primary endpoint in HER2-negative breast Bayer HealthCare and Onyx Pharmaceuticals Inc., an Amgen subsidiary, today announced that an investigational Phase 3 trial of NEXAVAR (sorafenib) tablets in patients with advanced breast cancer did not meet its primary endpoint of improving progression-free survival (PFS). More...

Reply

« Previous Thread | Next Thread »

Posting Rules
You may not post new threads You may not post replies You may not post attachments You may not edit your posts BB code is On Smilies are On [IMG] code is On HTML code is Off Forum Rules

All times are GMT -7. The time now is 09:41 PM.

free webpage hit counter